Achilles CHIRON ATX-NS-001 (Non-Small Cell Lung Cancer)
What is the Purpose of this Study?
If you choose to join this study, you will:
- Receive the study drug (ATL001) by IV alone or in combination with pembrolizumab
- Give tumor tissue
- Have physical exams, blood and urine tests
- Have eye exams
- Have imaging scans (CT and/or MRI)
- Have heart scans (ECG)
- Have lung function tests
- Receive the study drug (ATL001) by IV alone or in combination with pembrolizumab
- Give tumor tissue
- Have physical exams, blood and urine tests
- Have eye exams
- Have imaging scans (CT and/or MRI)
- Have heart scans (ECG)
- Have lung function tests
What is the Condition Being Studied?
Advanced Non-Small Cell Lung Cancer (NSCLC)
Who Can Participate in this Study?
Adults who are diagnosed with NSCLC.
For more information about who can join this study, please contact the study team at CCI-TrialReferrals@duke.edu or 919-681-6468.
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to understand whether an investigational therapy called ATL001 is a safe and beneficial treatment for people with NSCLC. This is the first study of ATL001.
Study Details
Full Title
An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON)
Principal Investigator
Protocol Number
IRB:
PRO00106642
NCT:
NCT04032847
ClinicalTrials.gov
View on ClinicalTrials.gov